-
Maxim: Our Vertex Pharma Thesis Is Unchanged
Friday, March 20, 2015 - 11:29am | 291In a report published Friday, Maxim Group analyst Jason Kolbert said that his thesis on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) remains unchanged for the following reasons: Kalydeco (ivafcaftor) has been approved for children with one of ten gating/conductance mutations, adding an...